2022 Fiscal Year Final Research Report
development of a novel drug delivery system of calpain
| Project/Area Number |
19K09926
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
阿部 俊明 東北大学, 医学系研究科, 教授 (90191858)
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 網膜色素変性 / カルパイン / 視細胞保護 |
|---|
| Outline of Final Research Achievements |
Since mitochondrial calpain, a type of calpain, activates apoptosis-inducing factor, we hypothesized that suppressing calpain might inhibit photoreceptor cell death to some extent, The results were compared with those of control eyes. In this study, right eyes of six rhodopsin P23H transgenic rats were used as the treated eyes and the left eyes as the control eyes, and the rats were followed up for 3 months. Results showed that there were no significant differences between the two groups in optical coherence tomography, electroretinogram, and fundus photographs for 3 months, and no differences in findings between the two groups in histological examination and transmission electron microscopy findings at 3 months.
|
| Free Research Field |
眼科学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は網膜色素変性という本邦における成人中途視覚障害原因第２位（14％）の疾患に対する治療法開発という意義をもつ。本疾患には現在のところ有効な治療法がなく、遺伝子治療、再生医療および人工視覚などの最先端技術を駆使した治療法が開発されつつあるが、いずれも高額な予算を必要とするため、医療費負担が大きくなると予想される。その点、薬物療法は視細胞保護治療として多くの患者に比較的安価にしかも繰り返し施行できる利点がある。もし、この方法の有効性が確認され、カルパイン阻害を主体とした新規視細胞保護治療法が実用化されれば、本疾患患者への恩恵は計り知れないと確信している。
|
